1 Comparing Cadence vs. Machine Learning based Physical Activity Intensity 2 Classifications: Variations in the Associations of Physical Activity with Mortality

3

```
Le Wei<sup>1,2</sup>, Matthew N. Ahmadi<sup>1,2</sup>, Raaj Kishore Biswas<sup>1,2</sup>, Stewart G. Trost<sup>3,4</sup>, Emmanuel
Stamatakis<sup>1,2*</sup>
```

6

7 Author Details

8	1.	Mackenzie	Wearables	Research	Hub,	Charles	Perkins	Centre,	The	University	of
9		Sydney, Syd	dney, Austra	alia							

- 10 2. School of Health Sciences, Faculty of Medicine and Health, The University of Sydney,
- 11 Sydney, Australia
- 12 3. School of Human Movement and Nutrition Sciences, The University of Queensland,
- 13 St Lucia, Queensland, Australia
- Children's Health Queensland Hospital and Health Service. Centre for Children's
 Health Research, South Brisbane, Queensland, Australia
- 16
- 17 Corresponding author
- 18 Professor Emmanuel Stamatakis
- 19 Address: Hub D17, Charles Perkins Centre L6 West, the University of Sydney, New South
- 20 Wales, Australia.
- 21 Email address: <u>emmanuel.stamatakis@sydney.edu.au</u>
- 22
- 23 Word count:
- 24 **Main text:** 4019 words
- 25 Abstract: 281 words

26

27 Acknowledgements

- 28 This research has been conducted using the UK Biobank Resource under Application
- 29 Number 25813. The authors would like to thank all the participants and professionals

30 contributing to the UK Biobank.

31 Funding

- 32 This study was funded by the National Health and Medical Research Council (NHMRC)
- through a Leadership level 2 Fellowship to Emmanuel Stamatakis (APP1194510).

34 Authors' contributions

- E.S., M.N.A, L.W., R.K.B, and S.G.T contributed to the study conception and design, and
- 36 interpretation of data. Data preparation was performed by M.N.A. The draft of the manuscript
- and data analysis were performed by L.W. All authors revised it critically and gave final
- approval and agreed to be accountable for all aspects of the work, ensuring integrity and
- 39 accuracy.

40 Conflict of Interest Statement

41 The authors declare that they have no conflict of interest.

42 Ethics approval

- 43 Our study utilized data from the UK Biobank, which has received ethical approval from the
- 44 National Research Ethics Service (Ref 11/NW/0382).

45 Informed Consent

46 Informed consent was obtained from all individual participants included in the study.

47 Data Availability Statement

- 48 This research has been conducted using the UK Biobank Resource under Application
- 49 Number 25813. Bona fide researchers can register and apply to use the UK Biobank dataset
- 50 at http://ukbiobank.ac.uk/register-apply/.
- 51
- 52
- 53
- 22
- 54

55 Abstract

56

57 *Background:* Step cadence-based and machine-learning (ML) methods have been used to 58 classify physical activity (PA) intensity in health-related research. This study examined the 59 association of intensity-specific PA daily duration with all-cause (ACM) and CVD mortality 50 varied among cadence-based and ML methods in 68,561 UK Biobank participants.

61 *Methods:* The two-stage-ML method categorized activity type and then intensity. The one-

62 level-cadence method (1LC) derived intensity duration using all detected steps and cadence

- 63 thresholds of ≥ 100 steps/min (moderate intensity) and ≥ 130 steps/min (vigorous intensity).
- The two-level-cadence method (2LC) detected ambulatory activities and then steps with the same cadence thresholds.

66 *Results:* The 2LC exhibited the most pronounced association at the lower end of the duration, 67 e.g., the 2LC showed the smallest minimum moderate-to-vigorous PA (MVPA) duration 68 (amount associated with 50% of optimal risk reduction) (2LC vs 1LC vs ML, 2.8 minutes/day [95% CI: 2.6, 2.8] vs 11.1 [10.8, 11.4] vs 14.9 [14.6, 15.2]) while exhibiting similar 69 70 corresponding ACM hazard ratio (HR) among methods (HR: 0.83 [95% CI: 0.78, 0.88] vs 71 0.80 [0.76, 0.85] vs 0.82 [0.76, 0.87]). The ML elicited the greatest mortality risk reduction, 72 e.g., for VPA-ACM association, 2LC vs 1LC vs ML: median, 2.0 minutes/day [95% CI: 2.0, 73 2.0] vs 6.9 [6.9, 7.0] vs 3.2 [3.2, 3.2]; HR, 0.69 [0.61, 0.79] vs 0.68 [0.60, 0.77] vs 0.53 [0.44, 74 0.64]. After standardizing duration, the ML exhibited the most pronounced associations, e.g., 75 for MPA-CVD mortality, 2LC vs 1LC vs ML, standardized minimum-duration: -0.77 vs -76 0.85 vs -0.94; HR 0.82 [0.72, 0.92] vs 0.79 [0.69, 0.90] vs 0.77 [0.69, 0.85].

Conclusion: The 2LC exhibited the most pronounced association with mortality at the lower
end of the duration. The ML method provided the most pronounced association with
mortality after standardizing the durations.

80

Key words: all-cause mortality, CVD mortality, moderate-to-vigorous intensity, step
cadence, walking

- 83
- 84
- 85
- 86

87 **1. Introduction**

88

Current PA guidelines recommend weekly 150-300 moderate-to-vigorous intensity physical 89 activity (MVPA) mins, or 75-150 vigorous intensity PA (VPA) mins and emphasize health 90 benefits of all PA bouts regardless of their duration^{1,2}. However, most of these guidelines 91 were derived from self-reports which typically fail to recognize the health value of short PA 92 bout (e.g., < 10-minute bout)³, thus affecting the accuracy of the estimates of the health 93 impact of different PA intensities. Recent studies have shown that the short intermittent 94 activity bursts were beneficially associated with long term health risks (e.g., all-cause^{4,5}, 95 CVD⁴ and cancer mortality risk⁴, and CVD⁵ and cancer⁶ incidence). The advancements in 96 97 wearables measurement technology and methods for processing and analyzing large volumes of accelerometer data provide researchers with multiple options for classifying PA intensity 98 within the short bout. Besides the more recent machine learning (ML) classification models⁷, 99 other methods include cut-points or thresholds based on proprietary activity counts ⁸ or 100 gravitational units⁹, or step cadence thresholds¹⁰. 101

The step cadence of ≥ 100 steps/min has been examined as a heuristic threshold for 102 moderate-to-vigorous intensity for adults in both treadmill and overground walking ¹⁰⁻¹⁴. 103 Similarly, a cadence of \geq 130 steps/min has been proposed as the heuristic threshold for 104 vigorous intensity among young and middle-aged adults^{10,11}. The step cadence methods are 105 feasible with any accelerometer providing researchers with a relatively simple method to 106 107 estimate the association of duration of PA across intensities with health outcomes in free-108 living samples. Prior studies have applied cadence thresholds to examine the association of PA intensities duration with various health outcomes ^{15–21}. For instance, a harmonized meta-109 110 analysis including 15 international accelerometry cohorts (13 waist, 1 thigh, 1 wrist) found that the association of the duration of moderate or higher intensity (defined as ≥ 100 111 steps/min) with mortality was attenuated after adjusting for total step counts, albeit remained 112 significant ¹⁵. Moreover, step is the fundamental unit of the ambulatory PA, step cadence-113 based thresholds may help people understand and monitor their required higher intensity PA 114 minutes (e.g., at least 150 MPA minutes per week) ^{1,2,22} and support more people to be 115 sufficiently active 23 . 116

ML methods have gained considerable attention in PA research recent years due to the increasing application of accelerometers and accessibility to raw data (gravitational acceleration)²⁴. By training a model with "features" of the accelerometer signal, such as time and frequency domain, that are extracted from the raw data, ML models classify patterns in

the raw accelerometer signal corresponding to an activity type or intensity ²⁴. ML algorithm 121 122 has the advantage of high accuracy in identifying different PAs and intensities in both lab and free-living environments ^{7,25,26}. Recent observational studies applying the ML method 123 showed that approximately daily 2-3 short bouts or 3-4 minutes of vigorous intermittent 124 125 lifestyle PA (VILPA) or 1-5 MV-ILPA minutes were associated with substantially reduced mortality risk, and cancer and CVD incidence⁴⁻⁶, amounts that are considerably lower than 126 current major PA guidelines recommendations (at least 75 weekly VPA mins or 150 MPA 127 128 mins)^{1,2,22} primarily based on questionnaire-based data. Prior research indicated that the ML 129 method demonstrated significantly higher agreement with ground-truth PA intensity than cutpoint (counts) methods for preschool children in free-living environment²⁷. 130

A recent unpublished study of ours ²⁸ indicated that the intensity-specific PA daily 131 132 duration estimates based on step cadence thresholds were substantially different to those 133 derived using the ML methods (mean absolute difference for MVPA: 24.2 mins/day). Such 134 differences prompt the question of whether the PA intensity-mortality associations differ by intensity classification method in free-living conditions. To our knowledge, no previous study 135 136 has examined the extent to which association between the duration of the PA intensity and 137 mortality varies according to multiple methods derived by processing the accelerometer data 138 to estimate PA intensity. Such information is important for guiding analytic and resource 139 allocation decisions in observational research and for understanding the role of PA intensity 140 classification in health research. The purpose of this study was to compare the association of intensity-specific daily PA duration with all-cause and CVD mortality, derived from two step 141 142 cadence-based and one ML method, in a large UK cohort with wrist-worn accelerometer data. 143

144 **2. Materials and Methods**

145

146 2.1 Participants

The UK Biobank is a large prospective cohort with 502,616 aged 40-69 years UK adults
recruited between 2006 and 2010²⁹. Participants completed baseline measurements and
provided written consent to use their data. The ethical approval was provided by the UK
National Health Service, National Research Ethics Service (Ref 11/NW/0382).

From 2013 to 2015, 103,684 UK biobank participants were sent and wore the Axivity AX3 wrist-worn triaxial accelerometer (Newcastle upon Tyne, UK) on their dominant wrist for 7 days continuously. The AX3 was initialized to capture triaxial acceleration data at a

5

154 sampling frequency of 100 Hz and a dynamic range of ± 8 g. A monitoring day was 155 considered valid if the wear time exceeded 16 hours. Participants returned the devices by mail and the data were calibrated ³⁰ and non-wear periods were identified ³¹. Participants 156 needed at least four valid monitoring days including a minimum of one valid weekend day to 157 be included in our study. As previous study⁷, we excluded participants with missing 158 covariate data, CVD and cancer history (ascertained through hospital admission records), and 159 160 outcome events occurring within one year after the PA assessment. In total, 68,561 161 participants were included in our study (Supplementary figure 1).

162

164

163 2.2 Physical activity intensity classification methods

165 2.2.1 Machine learning method

166 This two-stage classifier first applied a validated random forest (RF) classifier trained on 48 167 time and frequency domain features to categorize each 10-second window into one of the 168 four PA classes: sedentary (sitting still, reclined, etc.), standing utilitarian movements 169 (standing stationary/active standing: washing dishes, ironing a shirt, etc.), walking activities (active commuting, ambulatory gardening, etc.), or running/energetic activity (chasing 170 around with children, etc.)⁷. Time windows classified as walking were assigned to different 171 172 PA intensity bands using ambulatory acceleration thresholds and those classified as 173 running/energetic activities were classified as vigorous (≥ 6 METs). Time windows classified 174 as walking with normalized gravitational units < 100 milli g's were considered LPA (<3 175 METs) and those classified as walking with normalized gravitation units ≥ 100 milli g and <176 400 milli g were considered MPA (3-6 METs). The time windows classified as walking with 177 normalized gravitation units \geq 400 milli g walking activities were considered vigorous PA (VPA) (≥ 6 METs) 32,33 . Windows classified as sedentary behaviors were considered 178 179 sedentary (< 1.5 METs). We calculated the mean daily duration across intensities by 180 averaging over valid monitoring days.

181

182 2.2.2 One-level cadence method

We classified PA intensities using a validated one-level cadence method ¹⁰ (1LC). We implemented an open-source Windowed Peak Detection algorithm on the raw acceleration signal to detect steps ³⁴. This algorithm demonstrated high accuracy (Mean 89%, SD 12%) during treadmill and outdoor walking ³⁴. We calculated the step counts within each 60-second window and classified MPA, VPA and MVPA based on previously published step cadence thresholds (10–14). MPA was defined as a cadence ≥ 100 and <130 steps/min, VPA was defined as ≥ 130 steps/min, MVPA was defined as ≥ 100 steps/min. We considered a cadence of ≥ 20 and < 100 steps/min as light-PA (LPA). We used 20 steps/min as the lower cut-point for LPA to avoid misclassifying shuffling or pottering steps that occur in the 60-second window.

193

194 2.2.3 Two-level cadence method

195 Accurate step detection is challenging in free-living environments. A study showed that 196 routinely above 20% mean average percentage error (MAPE) existed in step counting accuracy in wrist-worn accelerometer cohort studies ³⁵, likely due to the random wrist and 197 upper limb movement (e.g., eating, brushing teeth, typing keyboard) misclassified as "steps". 198 199 To improve step counting accuracy, a hybrid two-level cadence method was developed (2LC). 200 Firstly, we identified stepping activities (e.g., walking, running) by applying the RF classifier 201 used in the ML method. Secondly, we summed up the step counts in 10-second windows 202 classified as walking within each non-overlapping one minute interval, and classified that minute as LPA, MPA and VPA based on the same cadence thresholds applied in 1LC 10 . 203 204 Then we added up the minutes corresponding to each intensity level, respectively, and 205 calculated the mean daily duration across intensities by averaging over valid monitoring days. 206

207 *2.3 Outcome ascertainment*

Participants were followed up until 30 November 2022. The deaths records were obtained through linkage with the National Health Service (NHS) Digital of England and Wales or the NHS Central Register and National Records of Scotland. Based on the ICD-10 (International Classification of Diseases, 10th revision) from both primary and contributory death cause, we defined CVD mortality as death from diseases of the circulatory system (ICD-10 codes: I0, I11, I13, I20–I51, I60–I69), excluding hypertension and diseases of arteries and lymph.

214

215 *2.4 Covariates*

We adjusted for covariates that are typical in studies examining intensity-specific PA and CVD risk based on previous peer-reviewed literature ³⁶. We included age, sex, ethnicity, accelerometer wear duration, LPA minutes, MPA minutes, VPA minutes, smoking status, 219 alcohol consumption, sleep duration, diet, screen time, education level, parental history of

220 CVD and cancer, and medication use of cholesterol, blood pressure, or diabetes.

221

222 2.5 Statistical analysis

223 To minimize the influence of the sparse data, we excluded the MVPA, MPA, and VPA duration derived from the cadence-based and ML method above the 95th percentile^{4,6,7}. We 224 225 examined the time-to-event dose-response association (hazard ratios [HRs]) of duration 226 across intensities classified from all three methods with ACM and CVD mortality using the 227 Cox proportional hazards regression with the 5th percentile of the duration across intensities 228 as the reference and age as timescale. We demonstrated the dose-response association using 229 the restricted cubic spline with knots placed at the 6th, 34th, and 67th percentile to fit the right-skewed distribution ⁶. We assessed the proportional hazards assumptions using 230 231 Schoenfeld residuals and observed no violations. We presented overlapping plots to visually 232 show and compare the dose-response associations of daily duration at each PA intensity with 233 ACM and CVD mortality across the cadence-based and ML methods. To compare across methods, we assessed the minimum dose ^{4,6,7}, 25th and 75th percentile dose (indicated by the 234 235 ED50, ED25, ED75 in figures and tables, which estimate the daily duration associated with 236 50%, 25% and 75% of the optimal risk reduction, respectively), and the optimal dose (the 237 nadir of the dose-response curve, representing the optimal risk reduction) and median daily 238 duration and their corresponding HRs (95% CI). We used bootstrapping with replacement 239 (1000 iterations) to calculate the 95% confidence interval for above metrics. We also assessed 240 the dose-response association of the standardized MVPA/MPA/VPA duration as computed 241 by each method (defined as absolute duration divided by the corresponding standard 242 deviation [SD]) with the two mortality outcomes.

To assess the robustness of our results, we performed the sensitivity analysis on the 90th percentile of dataset derived from each method to further minimise the influence of sparse minutes, and on the participants based on the 95th percentile of the 1LC method.

We performed all analyses using *R* software (version 4.2.2) and fitted models using *rms* package (version 6.3.0).

248

249 **3. Results**

250 *3.1. Description of the study sample*

Supplementary Table 1 shows the characteristics of the sample derived by the 1LC method in MVPA minutes, stratified by quartiles of daily MVPA minutes. The mean (SD) age was 61.8 (7.8), and 39,847 (58.1%) were women. Over a mean follow-up 8.0 (0.9) years, there were 2134 deaths, of which 575 were due to CVD related causes. Supplementary Fig. 1 shows the complete sample deprivation process.

256

257 3.2. Associations of daily MVPA with all-cause and CVD mortality

258 Fig. 1 shows that the L-shaped dose-response curve of MVPA duration with ACM derived 259 from the ML and 1LC method were similar, which the association decreased in a near-linear 260 fashion up to a similar nadir point (optimal duration: ML, 32.0 (30.3, 33.9), HR, 0.63 (0.53, 261 0.75); 1LC, 31.9 (30.0, 34.7), HR, 0.60 (0.53, 0.69)) and then increased in a near-linear 262 fashion with 95% CI largely overlapped. The L-shaped association derived from the 2LC 263 method exhibited a more pronounced ACM risk reduction than other methods till reaching its nadir point. The median, minimum, 25th, 75th and the optimal doses in 2LC were substantially 264 smaller than those in the 1LC and ML method, with slightly higher corresponding ACM HRs, 265 266 e.g., the minimum dose (Supplementary Table 2): ML vs 1LC vs 2LC, 14.9 (95% CI: 14.6, 267 15.2) vs 11.1 (10.8, 11.4) vs 2.8 (2.6, 2.8), HR: 0.82 (95% CI: 0.76, 0.87) vs 0.80 (0.76, 0.85) 268 vs 0.83 (0.78, 0.88). Fig. 2 shows that the association derived from the 2LC method exhibited 269 a more pronounced CVD risk reduction than other methods until its nadir point. ML method 270 provided the lowest CVD HR across all the metrics among the methods, e.g., the ED75 dose, 271 ML vs 2LC, 20.0 (19.0, 23.5) vs 5.6 (4.1, 9.9); HR: 0.60 (0.50, 0.71) vs 0.69 (0.58, 0.83) 272 (Supplementary Table 3). However, there was less evidence (wider 95% CI) for CVD 273 mortality than ACM due to fewer CVD mortality events.

274

275 *3.3. Associations of MPA duration with all-cause and CVD mortality*

Fig. 3 shows that the L-shaped dose-response association of MPA mins between the ML and
1LC method with ACM were similar with 95% CI largely overlapped, and both methods
exhibited linear inverse association up to around the median duration (ML:32.2 [32.1, 32.3],
HR, 0.60 [0.51, 0.70]; 1LC: 19.9 [19.9, 20.0], HR, 0.65 [0.58, 0.73]) (Supplementary Table
where the curve flattened. Meanwhile, the 2LC method exhibited steeper risk reduction in
a near-linear fashion up to its median (5.3 [5.3, 5.4], HR, 0.68 [0.60, 0.77]) and continued to

282 show more risk reduction than other methods until 20 MPA minutes. The ML method provided substantially larger minimum, 25th, and 75th percentile durations than the 1LC and 283 2LC methods, with more ACM risk reduction, e.g., the minimum dose (Supplementary 284 Table 2): ML vs 1LC vs 2LC, 14.9 (95% CI: 14.6, 15.2) vs 8.6 (8.3, 9.3) vs 2.3 (2.1, 2.8). 285 286 HR: 0.77 (0.70, 0.83) vs 0.81 (0.76, 0.86) vs 0.82 (0.77, 0.88). Fig. 4 shows that L-shaped 287 beneficial association with CVD mortality across methods, respectively, was similar to that in 288 the MPA-ACM association in terms of the dose-response curve and other metrics 289 (Supplementary Table 3), except for the upward pattern of the 2LC method after the median 290 MPA mins (roughly 6 mins).

291

292 3.4. Associations of VPA duration with all-cause and CVD mortality

293 Fig. 5 shows that the 1LC method provided the least pronounced dose-response association 294 of VPA mins with ACM, and the ML method provided the most pronounced one, e.g., the 295 median (Supplementary Table 2): ML, 3.2 (95% CI: 3.2, 3.2), HR, 0.53 (95% CI: 0.44, 296 0.64); 1LC, 6.9 (6.9, 7.0), 0.68 (0.60, 0.77); 2LC, 2.0 (2.0, 2.0), 0.69 (0.61, 0.79). The dose-297 response association of the 2LC method was almost identical to that of the ML method up to 298 roughly 1.5 mins, with both methods showing steep risk reduction. The ML method further 299 exhibited steep ACM risk reduction up to around its median point and demonstrated 300 substantially lower ACM risk reduction than that of the 2LC method. Fig. 6 shows that the 301 dose-response association of VPA minutes derived by the 2LC method with CVD mortality 302 exhibited more pronounced risk reduction compared to the ML method up to around 10 303 minutes where the curve flattened. The 2LC method provided smaller dose but higher 304 corresponding CVD HRs for most point estimates, e.g, the minimum point (Supplementary 305 Table 3): ML: 9.0 (7.4, 9.3), HR, 0.70 (0.60, 0.81); 2LC, 0.6 (0.4, 0.9), HR, 0.75 (0.67, 306 0.85). However, there was less evidence (wider 95% CI) for CVD mortality than ACM due to 307 fewer CVD mortality events.

308

309 3.5. Associations of the standardised duration with all-cause and CVD mortality

Supplementary Fig 2-4 show that the dose-response associations of standardized duration with ACM across intensities, respectively, was similar between the 1LC and 2LC method, 312 with 95% CI largely overlapped. The ML method provided the most pronounced association 313 of standardized duration with ACM across intensities, especially for the standardized VPA 314 minutes-ACM association (Supplementary Fig 4), e.g., for the median of the standardized 315 VPA minutes/day and the corresponding HR (ML: -0.31, HR, 0.53 (0.44, 0.64); 1LC: -0.35, 316 HR, 0.68 (0.60, 0.77); 2LC: -0.39, HR, 0.71, (0.63, 0.81)) (Supplementary Table 4). 317 Supplementary Table 4 shows that almost all the metrics related to MPA and VPA between 318 the 2LC and the ML method were different. **Supplementary Fig 5 and 7** show that the 95% 319 CI of the L-shaped dose-response association of the standardized MVPA and VPA duration 320 with CVD mortality were largely overlapped. Supplementary Fig 6 shows that the ML 321 method provided the most pronounced association of standardized MPA duration with CVD 322 mortality compared to other methods, e.g., for the median of the standardized MPA 323 minutes/day and the corresponding HR (ML: -0.20, HR, 0.54 (0.43,0.68); 1LC: -0.27, HR, 324 0.59 (0.43,0.81); 2LC: -0.35, HR, 0.64 (0.48, 0.86)) (Supplementary Table 5). We observed 325 less evidence (wider 95% CI) for association of standardized duration with CVD mortality 326 due to fewer CVD mortality events than ACM.

327

328 **4. Discussion**

329 To our knowledge, this is the first study to compare the dose-response associations of 330 different PA intensity classification methods (cadence-based methods and ML method) with 331 standard health outcomes used routinely in observational studies. The ML and 1LC methods 332 provided similar dose-response associations. The 2LC method exhibited the most pronounced 333 rate of decrease in the association with mortality across intensities at the lower end of the 334 duration. The ML elicited more risk reduction in mortality than cadence-based methods, 335 particularly for the VPA-ACM association. The ML method provided the most pronounced 336 dose-response associations of the standardized duration with mortality outcomes across 337 different intensity levels. Future research could focus on deriving the cadence-thresholds for 338 short windows, e.g., 10-second window for each PA intensity level, to inform the step-based 339 public health guideline and interventions, etc.

A potential explanation for the variation in dose-response associations is the different window length applied in the 2LC and ML method. Our ML method classified PA intensity using 10-second window, enabling the detection of finer pattern of MVPA derived by very brief bouts, thus leading to different dose-response association relative to the 2LC method 344 which applied 60-second window. The shorter window is more likely to detect MVPA burst ³⁷. Prior studies applying various window lengths (15 seconds, 30 seconds, 60 seconds) 345 demonstrated that shorter windows detect significantly more MVPA minutes ^{27,38}. Applying a 346 longer epoch such as 60-seconds window might result in a smoothing effect ³⁹, e.g., a 30-347 348 second jogging to catch bus (MVPA burst) might be degraded to lower intensity using 2LC 349 method. A recently published large cohort study has indicated that the MVPA accumulated 350 through bouts that less than 1 min (with VPA being at least 15% proportion of the MVPA time) would elicit beneficial change on ACM risk ⁵. Such smoothing effect cause higher 351 352 intensity PA to decrease to a lower level, potentially misleading researchers to unreliable 353 intensity time - morality association and therefore overlooked the health effect of the 354 valuable granularity of intensity time.

355 Another potential explanation is that the 2LC method, although be able to detect stepping 356 activities and thus counting steps accurately, might overlook the variation in step intensity 357 (e.g., steps involving upper-body movements). The ML method, in conjunction with the wrist accelerometer, could detect steps associated with upper-body movements ⁴⁰ (e.g., ambulatory 358 359 gardening), thus capturing wider range of PAs and providing more representative duration of 360 PA intensities than 2LC method. Prior studies have indicated that PAs involving upper-body 361 movements such as occupational and household activities account for a large proportion of 362 MVPA time (e.g., the household PAs was the most prevalent domain for those who reported under weekly 150 MVPA mins)⁴¹. 363

364 The association of the VPA duration derived by the ML method with ACM was similar to 365 that of 2LC method at the lower end of distribution (up to 2 mins), suggesting that these VPA 366 duration might be the result of incidental brisk walking or running (e.g., quickly moving for 10 seconds). Prior study has shown that a large portion (92.3%) of VILPA bouts in non-367 exercisers were less than a minute ⁴. The 2LC using 60-seconds window may overlook many 368 369 such bursts and thus unlikely to derive the dose-response association close to ML method in 370 free-living environment. The ML-derived VPA dose-response association appeared the 371 steepest HR reduction for ACM with the lowest HR associated in all point estimates, 372 suggesting that the VPA duration including granularity duration might demonstrate more 373 beneficial change on ACM than that of the VPA duration calculated based on step counts per 374 min. This enhanced the value of the short VPA burst for achieving beneficial health change.

After standardization of the MVPA/MPA/VPA minutes, the dose-response association with mortality between the 2LC and the ML method showed variation in terms of the curve and most point estimates. This was especially evident in the association of standardized VPA duration with the ACM. This finding implied that the propensity of the estimation methods
not only provide different estimates of the duration, but also the additional duration of the
MVPA/MPA/VPA bursts detected by the ML method elicited higher degree of mortality risk
reduction than other methods. This enhanced the role of the short bout higher intensity PA in
potentially beneficial changes on health.

383 Wrist, as the most active part of body, produces many extraneous wrist movements (e.g., 384 eating) which might be recorded as ambulatory by wrist-worn accelerometers ("error steps") 385 ⁴². Although the 1LC method was based on the same cadence-thresholds as 2LC, it counted 386 steps without identifying the stepping activities first, which leads to substantial higher "error 387 steps" counts than the 2LC method. Therefore, the 1LC method inflated MVPA/MPA 388 durations and thus derived similar association to the ML method. A study comparing the step 389 detection accuracy of 13 wearables found that wrist-worn accelerometers detected roughly 450 more steps per day than waist-worn in free-living environment ⁴³. The inflated 390 391 MVPA/MPA duration might lead to associations with mortality close to that of ML method. 392 Nonetheless, the inherent randomness in wrist movements might introduce variations in error 393 steps count, influenced by factors such as the variation of wrist-movements, sample 394 characteristics or step-detection methods making 1LC-derived dose-response association with 395 mortality unstable.

396 To our knowledge, this is the first study comparing the PA intensity classification 397 methods (cadence-based and ML method) in terms of the association with standard health 398 outcomes used routinely in observational studies. Our study had large sample with long 399 follow-up years. The ML method could detect the micro-pattern of PA and upper-body 400 movements in free-living environment. The 2LC method used advanced step detection 401 algorithm and provide better accuracy. We have conducted multiple sensitivity analyses to 402 show robustness of our findings. Our study had several limitations. Our study categorized 403 confounders (e.g., sleep duration, LPA) to avoid statistical assumption violation. The ML 404 method is not the ground-truth PA intensity time estimation method, although showed high accuracy for MPA (precision: 92.7) and VPA (94.6) comparing to the criterion data⁷. The 405 406 measurement error in the ML method for PA intensity time might affect the comparison of 407 the intensity time - mortality association among methods. The UK biobank has a low response-rate (5.5%) and thus not representative of the population ⁴⁴, although a study has 408 demonstrated that poor representativeness in UK biobank didn't materially affect the PA-409 mortalities associations ⁴⁵. 410

411

412 **5. Perspective**

413 The 1LC method produced similar dose-response MVPA/MPA-mortality associations to the 414 ML method. The 2LC method exhibited the most pronounced associations with mortality 415 across intensities than the ML method at lower end of the duration. The ML method elicited 416 more risk reduction in mortality than cadence-based methods, particularly for the VPA-ACM 417 association. After standardization of the duration, the ML method generally provided most 418 pronounced associations across intensities. These suggested that the MPA/VPA bursts 419 detected by the shorter detection window (10-second) in the ML method can capture the 420 associations between activities and health outcomes with greater granularity. The method that 421 based on the threshold of walking steps in a minute long window might underestimate both 422 the duration and potential health benefits of the MPA and VPA bouts under the free-living 423 conditions. Future studies could focus on the cadence-based thresholds for windows less than 424 a minute for detecting the MPA and VPA bursts.

425

426 Acknowledgements

427 This research has been conducted using the UK Biobank Resource under Application

428 Number 25813. The authors would like to thank all the participants and professionals

429 contributing to the UK Biobank.

430 Funding

431 This study was funded by the National Health and Medical Research Council (NHMRC)

through a Leadership level 2 Fellowship to Emmanuel Stamatakis (APP1194510).

433 Authors' contributions

434 E.S., M.N.A, L.W., R.K.B, and S.G.T contributed to the study conception and design, and

435 interpretation of data. Data preparation was performed by M.N.A. The draft of the manuscript

and data analysis were performed by L.W. All authors revised it critically and gave final

437 approval and agreed to be accountable for all aspects of the work, ensuring integrity and438 accuracy.

439 **Conflict of Interest Statement**

440 The authors declare that they have no conflict of interest.

14

441 Informed Consent

- 442 Informed consent was obtained from all individual participants included in the study.
- 443
- 444
- 445

446 **References**

- Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med*. 2020;54(24):1451-1462. doi:10.1136/bjsports-2020-102955
- Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA Journal of the American Medical Association. 2018;320(19):2020-2028.
 doi:10.1001/jama.2018.14854
- 4533.Sallis JF, Saelens BE. Assessment of physical activity by self-report: Status, limitations, and454future directions. Res Q Exerc Sport. 2000;71:1-14. doi:10.1080/02701367.2000.11082780
- 455 4. Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured vigorous
 456 intermittent lifestyle physical activity with mortality. *Nat Med.* 2022;28(12):2521-2529.
 457 doi:10.1038/s41591-022-02100-x
- Ahmadi MN, Hamer M, Gill JMR, et al. Brief bouts of device-measured intermittent lifestyle
 physical activity and its association with major adverse cardiovascular events and mortality in
 people who do not exercise: a prospective cohort study. *Lancet Public Health*.
 2023;8(10):e800-e810. doi:10.1016/S2468-2667(23)00183-4
- Stamatakis E, Ahmadi MN, Friedenreich CM, et al. Vigorous Intermittent Lifestyle Physical
 Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry
 Study. JAMA Oncol. Published online July 27, 2023. doi:10.1001/jamaoncol.2023.1830
- Ahmadi MN, Clare PJ, Katzmarzyk PT, del Pozo Cruz B, Lee IM, Stamatakis E. Vigorous physical
 activity, incident heart disease, and cancer: how little is enough? *Eur Heart J*. Published online
 December 7, 2022. doi:10.1093/eurheartj/ehac572
- 468 8. Trost SG, Mciver KL, Pate RR. Conducting accelerometer-based activity assessments in field469 based research. In: *Medicine and Science in Sports and Exercise*. Vol 37. ; 2005.
 470 doi:10.1249/01.mss.0000185657.86065.98
- 471 9. Stemland I, Ingebrigtsen J, Christiansen CS, et al. Validity of the Acti4 method for detection of
 472 physical activity types in free-living settings: comparison with video analysis. *Ergonomics*.
 473 2015;58(6):953-965. doi:10.1080/00140139.2014.998724
- Tudor-Locke C, Ducharme SW, Aguiar EJ, et al. Walking cadence (steps/min) and intensity in
 41 to 60-year-old adults: the CADENCE-adults study. *International Journal of Behavioral Nutrition and Physical Activity*. 2020;17(1). doi:10.1186/s12966-020-01045-z

477 11. Tudor-Locke C, Aguiar EJ, Han H, et al. Walking cadence (steps/min) and intensity in 21-40 478 year olds: CADENCE-adults. International Journal of Behavioral Nutrition and Physical Activity. 479 2019;16(1). doi:10.1186/s12966-019-0769-6 480 12. Tudor-Locke C, Mora-Gonzalez J, Ducharme SW, et al. Walking cadence (steps/min) and 481 intensity in 61–85-year-old adults: the CADENCE-Adults study. International Journal of 482 Behavioral Nutrition and Physical Activity. 2021;18(1). doi:10.1186/s12966-021-01199-4 483 13. Aguiar EJ, Mora-Gonzalez J, Ducharme SW, et al. Cadence-based classification of moderate-484 intensity overground walking in 41- to 85-year-old adults. Scand J Med Sci Sports. Published 485 online 2022. doi:10.1111/SMS.14274 486 14. Aguiar EJ, Gould ZR, Ducharme SW, Moore CC, McCullough AK, Tudor-Locke C. Cadence-487 based Classification of Minimally Moderate Intensity during Overground Walking in 21- To 40-488 Year-Old Adults. J Phys Act Health. 2019;16(12):1092-1097. doi:10.1123/jpah.2019-0261 489 15. Paluch AE, Bajpai S, Bassett DR, et al. Daily steps and all-cause mortality: a meta-analysis of 490 15 international cohorts. Lancet Public Health. 2022;7(3):e219-e228. doi:10.1016/S2468-491 2667(21)00302-9 492 16. Paluch AE, Bajpai S, Ballin M, et al. Prospective Association of Daily Steps With Cardiovascular 493 Disease: A Harmonized Meta-Analysis. Circulation. Published online December 20, 2022. 494 doi:10.1161/CIRCULATIONAHA.122.061288 495 17. Blodgett JM, Ahmadi MN, Atkin AJ, et al. Device-measured physical activity and 496 cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) 497 consortium. Eur Heart J. Published online November 10, 2023. doi:10.1093/eurheartj/ehad717 498 499 18. Senaratne N, Stubbs B, Werneck AO, Stamatakis E, Hamer M. Device-measured physical 500 activity and sedentary behaviour in relation to mental wellbeing: An analysis of the 1970 501 British cohort study. Prev Med (Baltim). 2021;145. doi:10.1016/j.ypmed.2021.106434 502 19. Blodgett JM, Mitchell JJ, Stamatakis E, Chastin S, Hamer M. Associations between the 503 composition of daily time spent in physical activity, sedentary behaviour and sleep and risk of 504 depression: Compositional data analyses of the 1970 British cohort Study. J Affect Disord. 505 2023;320:616-620. doi:10.1016/j.jad.2022.09.110 506 20. Cooper R, Stamatakis E, Hamer M. Associations of sitting and physical activity with grip 507 strength and balance in mid-life: 1970 British Cohort Study. Scand J Med Sci Sports. 508 2020;30(12):2371-2381. doi:10.1111/sms.13793 509 Huang BH, Hamer M, Chastin S, Pearson N, Koster A, Stamatakis E. Cross-sectional 21. 510 associations of device-measured sedentary behaviour and physical activity with cardio-511 metabolic health in the 1970 British Cohort Study. Diabetic Medicine. 2021;38(2). 512 doi:10.1111/dme.14392 513 22. Ross R, Chaput JP, Giangregorio LM, et al. Canadian 24-Hour Movement Guidelines for Adults 514 aged 18-64 years and Adults aged 65 years or older: an integration of physical activity, 515 sedentary behaviour, and sleep. In: Applied Physiology, Nutrition, and Metabolism = 516 Physiologie Appliquee, Nutrition et Metabolisme. Vol 45. NLM (Medline); 2020:S57-S102. 517 doi:10.1139/apnm-2020-0467

518 23. Stamatakis E, Ahmadi M, Murphy MH, et al. Journey of a thousand miles: From 'Manpo-Kei' 519 to the first steps-based physical activity recommendations. Br J Sports Med. Published online 520 2023. doi:10.1136/bjsports-2023-106869 521 24. Narayanan A, Desai F, Stewart T, Duncan S, MacKay L. Application of raw accelerometer data 522 and machine-learning techniques to characterize human movement behavior: A systematic 523 scoping review. J Phys Act Health. 2020;17(3):360-383. doi:10.1123/jpah.2019-0088 524 25. Willetts M, Hollowell S, Aslett L, Holmes C, Doherty A. Statistical machine learning of sleep 525 and physical activity phenotypes from sensor data in 96,220 UK Biobank participants. Sci Rep. 526 2018;8(1). doi:10.1038/s41598-018-26174-1 527 26. Pavey TG, Gilson ND, Gomersall SR, Clark B, Trost SG. Field evaluation of a random forest 528 activity classifier for wrist-worn accelerometer data. J Sci Med Sport. 2017;20(1):75-80. 529 doi:10.1016/J.JSAMS.2016.06.003 530 27. Ahmadi MN, Pavey TG, Trost SG. Machine learning models for classifying physical activity in 531 free-living preschool children. Sensors (Switzerland). 2020;20(16):1-14. 532 doi:10.3390/s20164364 533 28. Le Wei, Matthew N. Ahmadi, Mark Hamer, et al. Comparing Cadence and ML based Estimates 534 for PA Intensities classification. Unpublished results 535 29. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the 536 Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Med. 2015;12(3). 537 doi:10.1371/journal.pmed.1001779 538 30. Sipoš M, Pačes P, Roháč J, Nováček P. Analyses of Triaxial Accelerometer Calibration 539 Algorithms. IEEE Sens J. 2012;12(5). doi:10.1109/JSEN.2011.2167319 540 31. Ahmadi MN, Nathan N, Sutherland R, Wolfenden L, Trost SG. Non-wear or sleep? Evaluation 541 of five non-wear detection algorithms for raw accelerometer data. Published online 2019. 542 doi:10.1080/02640414.2019.1703301 543 32. Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability of raw 544 accelerometer output from wrist-and hip-worn monitors. Med Sci Sports Exerc. 545 2014;46(9):1816-1824. doi:10.1249/MSS.000000000000289 546 33. Ramakrishnan R, Doherty A, Smith-Byrne K, et al. Accelerometer measured physical activity 547 and the incidence of cardiovascular disease: Evidence from the UK Biobank Cohort study. 548 PLoS Med. 2021;18(1). doi:10.1371/journal.pmed.1003487 549 34. Brondin A, Nordström M, Olsson CM, Salvi D. Open source step counter algorithm for 550 wearable devices. In: ACM International Conference Proceeding Series. Association for 551 Computing Machinery; 2020. doi:10.1145/3423423.3423431 552 35. Toth LP, Park S, Springer CM, Feyerabend MD, Steeves JA, Bassett DR. Video-Recorded Validation of Wearable Step Counters under Free-living Conditions. Med Sci Sports Exerc. 553 554 2018;50(6):1315-1322. doi:10.1249/MSS.000000000001569 555 36. Ahmadi MN, Clare PJ, Katzmarzyk PT, del Pozo Cruz B, Lee IM, Stamatakis E. Vigorous physical activity, incident heart disease, and cancer: how little is enough? Eur Heart J. Published online 556 557 October 27, 2022. doi:10.1093/eurheartj/ehac572

558 559	37.	Arvidsson D, Fridolfsson J, Börjesson M. Measurement of physical activity in clinical practice using accelerometers. <i>J Intern Med</i> . 2019;286(2):137-153. doi:10.1111/joim.12908
560 561 562	38.	Banda JA, Haydel KF, Davila T, et al. Effects of varying epoch lengths, wear time algorithms, and activity cut-points on estimates of child sedentary behavior and physical activity from accelerometer data. <i>PLoS One</i> . 2016;11(3). doi:10.1371/journal.pone.0150534
563 564 565	39.	Aadland E, Andersen LB, Anderssen SA, Resaland GK, Kvalheim OM. Associations of volumes and patterns of physical activity with metabolic health in children: A multivariate pattern analysis approach. <i>Prev Med (Baltim)</i> . 2018;115:12-18. doi:10.1016/j.ypmed.2018.08.001
566 567	40.	Liu F, Wanigatunga AA, Schrack JA. Assessment of Physical Activity in Adults Using Wrist Accelerometers. <i>Epidemiol Rev</i> . 2021;43(1):65-93. doi:10.1093/epirev/mxab004
568 569 570	41.	Strain T, Fitzsimons C, Foster C, Mutrie N, Townsend N, Kelly P. Age-related comparisons by sex in the domains of aerobic physical activity for adults in Scotland. <i>Prev Med Rep</i> . 2016;3:90-97. doi:10.1016/j.pmedr.2015.12.013
571 572 573	42.	Bassett DR, Toth LP, LaMunion SR, Crouter SE. Step Counting: A Review of Measurement Considerations and Health-Related Applications. <i>Sports Medicine</i> . 2017;47(7):1303-1315. doi:10.1007/s40279-016-0663-1
574 575 576	43.	Nakagata T, Murakami H, Kawakami R, et al. Step-count outcomes of 13 different activity trackers: Results from laboratory and free-living experiments. <i>Gait Posture</i> . 2022;98:24-33. doi:10.1016/j.gaitpost.2022.08.004
577 578 579	44.	Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those of the General Population. <i>Am J Epidemiol</i> . 2017;186(9):1026-1034. doi:10.1093/aje/kwx246
580 581 582	45.	Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is Cohort Representativeness Passé团? Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank. <i>Epidemiology</i> . 2021;32(2):179-188. doi:10.1097/EDE.000000000001316
583		
584		



Fig. 1 Association of the MVPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with all-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25% (ED25), 50% (ED50), and 75% (ED75) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, light physical activity duration, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Fig 2 Association of the MVPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25% (ED25), 50% (ED50), and 75% (ED75) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, Light PA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Fig. 3 Association of the MPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with all-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25% (ED25), 50% (ED50), and 75% (ED75) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, light PA, VPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Fig 4 Association of the MPA minutes derived from the cadence-based methods (1LC and 2LC)* and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25% (ED25), 50% (ED25), and 75% (ED25) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, light PA, VPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Fig. 5 Association of the VPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with all-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25%(ED25), 50% (ED50), and 75% (ED75) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). Adjusted for age, sex, wear time, light PA, MPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.

All-cause mortality



Fig 6 Association of the VPA minutes derived from the cadence-based methods (1LC and 2LC)* and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Cross, diamond, and triangle represent the daily MVPA minutes that associated with 25% (ED25), 50% (ED50), and 75% (ED75) of the optimal risk reduction, respectively, and circle represents the median daily MVPA minutes. Please see supplementary table 2 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, light PA, MPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.

CVD mortality



Supplemental fig 1 Flow diagram of participants



Supplementary fig 2 Association of the standardized MVPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with all-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised MVPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised daily median MVPA minutes across methods. Please see supplementary table 3 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.

All-cause mortality



Supplementary fig 3 Association of the standardized MPA minutes derived from the cadence-based methods (1LC and 2LC)* and machine learning (ML) method with All-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised MPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised median MPA minutes across methods. Please see supplementary table 3 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, VPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Supplementary fig 4 Association of the standardized VPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with all-cause mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised VPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised median VPA minutes across methods. Please see supplementary table 3 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, MPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Supplementary fig 5 Association of the standardized MVPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised MVPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised median MVPA minutes across methods. Please see supplementary table 4 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Supplementary fig 6 Association of the standardized MPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised MPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised median MPA minutes across methods. Please see supplementary table 4 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, VPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.



Supplementary fig 7 Association of the standardized VPA minutes derived from the cadence-based methods (1LC and 2LC) and machine learning (ML) method with CVD mortality. 1LC indicates the one-level cadence method. 2LC indicates the two-level cadence method. Diamond represents the minimum dose (ED50), which estimates the daily standardised VPA minutes associated with 50% of optimal risk reduction across methods. Circle represents the standardised median VPA minutes across methods. Please see supplementary table 4 for the list of metrics (duration and corresponding HR). The association was adjusted for age, sex, wear time, LPA, MPA, smoking status, alcohol consumption, sleep duration, diet, screen-time, education, self-reported parental history of CVD and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). The range was capped at the 95th percentile to minimize the influence of sparse data. All methods used their corresponding 5th percentile as the reference level to calculate each HR.

Supplementary Table 1 Characteristics of Participants, by quartile a of one-level

cadence method-derived MVPA minutes

		One-level	cadence meth	nod derived da	aily MVPA
			mir	nutes	
	Total	Quartile 1	Quartile 2	Quartile 3	Quartile 4
Total participants, n	68561	17186	17097	17138	17140
Male, n (%)	28714 (41.9)	6406 (37.3)	7011 (41.0)	7409 (43.2)	7888 (46.0)
wear_days, mean (sd)	6.8 (0.4)	6.8 (0.4)	6.8 (0.34)	6.8 (0.4)	6.8 (0.3)
follow-up year, mean (SD)	8.0 (0.9)	7.9 (1.0)	8.0 (0.9)	8.0 (0.8)	8.0 (0.8)
age, mean (SD)	61.8 (7.8)	64.2 (7.4)	62.1 (7.7)	61.0 (7.8)	59.9 (7.7)
Education, n (%)					
College or University degree	30237 (44.1)	6681 (38.9)	7267 (42.5)	7848 (45.8)	8441 (49.2)
A levels/AS levels or equivalent	9162 (13.4)	2255 (13.1)	2316 (13.5)	2319 (13.5)	2272 (13.3)
O levels/GCSEs or equivalent	14001 (20.4)	3820 (22.2)	3616 (21.1)	3446 (20.1)	3119 (18.2)
CSEs or equivalent	2804 (4.1)	673 (3.9)	696 (4.1)	688 (4.0)	747 (4.4)
NVQ or HND or HNC or equivalent	3512 (5.1)	957 (5.6)	924 (5.4)	842 (4.9)	789 (4.6)
Other professional qualifications e.g nursing, teaching	3327 (4.9)	1018 (5.9)	846 (4.9)	792 (4.6)	671 (3.9)
	66357	16668	16522	16574	16593
White ethnicity, n (%)	(96.8)	(97.0)	(96.6)	(96.7)	(96.8)
diet, mean (SD) ^b	7.9 (4.4)	7.8 (4.4)	7.8 (4.3)	7.9 (4.4)	8.1 (4.6)
Discretionary screen time, mean (SD) ^c	3.6 (2.1)	4.1 (2.3)	3.7 (2.1)	3.5 (2.1)	3.2 (2.0)
Medication, n (%)					
Cholesterol, n (%)	7927 (11.6)	2977 (17.3)	2055 (12.0)	1587 (9.3)	1308 (7.6)
Blood Pressure, n (%)	5792 (8.4)	2075 (12.1)	1498 (8.8)	1234 (7.2)	985 (5.7)
Diabetes, n (%)	83 (0.1)	21 (0.1)	20 (0.1)	21 (0.1)	21 (0.1)
sleep (hours per day), (mean (SD))	7.17 (0.98)	7.19 (1.06)	7.16 (0.98)	7.16 (0.94)	7.16 (0.92)

smokars n (%)	28659	7744 (45.1)	7170 (41.9)	6964 (40.6)	6781 (30.6)
	(41.8)				0781 (39.0)
Family history of CVD, n	37362	9881 (57.5)	9380 (54.9)	9128 (53.3)	8073 (52 4)
(%)	(54.5)				6975 (52.4)
Family history of cancer n	21207	5475 (31.9)	5339 (31.2)	5229 (30.5)	5164 (20.1)
(%)	(30.9)				5104 (50.1)
All cause mortality n (%)	2134	830 (4.0)	505 (3.0)	112 (2.6)	348 (2.0)
An-cause monanty, n (%)	(3.1)	039 (4.9)	505 (5.0)	442 (2.0)	548 (2.0)
CVD montality $n(0/)$	575	265(15)	117 (0 7)	110 (0.6)	82 (0 5)
C VD montanty, n (%)	(0.8)	203 (1.3)	117 (0.7)	110 (0.0)	85 (0.5)
Daily Durations across					
intensities and methods ^d					
MI MUPA (mogn (SD))	38.3	20.3 (13.9)	31.8 (17.6)	12 2 (22 3)	587(316)
	(26.5)		51.8 (17.0)	42.3 (22.3)	58.7 (51.0)
21 C MUPA (mean (SD))	12.2	23(20)	64(41)	126(80)	27.3 (19.8)
	(14.5)	2.3 (2.0)	0.4 (4.1)	12.0 (0.0)	27.3 (19.8)
IIC MVPA (mean (SD))	36.0	7 2 (3 5)	196(40)	37 3 (6 7)	799(235)
	(30.2)	7.2 (3.3)	17.0 (4.0)	57.5 (0.7)	19.9 (23.5)
ML MPA (mean (SD))	33.0	18 1 (12 6)	27.6 (16.1)	36 1 (20 6)	50.2 (30.0)
	(24.0)	10.1 (12.0)	27.0 (10.1)	50.1 (20.0)	50.2 (50.0)
2LC_MPA (mean (SD))	8.5 (9.4)	1.8 (1.5)	4.8 (3.0)	9.0 (5.4)	18.4 (12.4)
1LC_MPA (mean (SD))	25.3	57(28)	148(31)	269(51)	538(153)
	(19.9)	5.7 (2.0)	1 110 (5.1)	20.9 (0.1)	55.6 (15.5)
ML_VPA (mean (SD))	5.3 (6.0)	2.2 (3.3)	4.2 (4.5)	6.1 (5.7)	8.6 (7.7)
2LC_VPA (mean (SD))	3.7 (5.4)	0.6 (0.6)	1.7 (1.4)	3.6 (3.0)	8.9 (8.2)
ILC VPA (mean (SD))	10.7	16(10)	48(18)	104(34)	26.2 (10.5)
	(11.0)	1.0 (1.0)	4.0 (1.0)	10.4 (3.4)	20.2 (10.5)
MI_IPA (mean (SD))	119.4	108.9	118.9	123.4	126.3 (64.6)
	(62.9)	(59.9)	(62.5)	(63.2)	
21C IPA (mpan (SD))	116.7	76.2 (43.0)	107.2	128.8	154.7 (69.2)
	(63.4)		(51.6)	(58.7)	
IIC IPA (maan (SD))	254.3	199.8	250.3	274.9	292.4 (78.2)
ILC_LIA (mean (SD))	(79.8)	(67.1)	(68.4)	(73.0)	

^a Quartiles were categorized from low to high based on the one-level cadence method derived daily MVPA duration. This table was based on the 95th percentile of the one-level cadence derived MVPA sample.

^b fruit and vegetables servings per day

^c time spent watching TV and computer per day

Abbreviations: CVD, cardiovascular diseases; MVPA, moderate-to-vigorous intensity physical activity; MPA, moderate intensity physical activity; VPA, vigorous intensity physical activity; LPA, light intensity physical activity; machine learning method (ML), one-level cadence method (1LC), two-level cadence method (2LC); SD, standard deviation;

Supplementary table 2 The duration associated with the ED25, ED50, ED75, ED100 and the median of the intensities duration derived from cadence-based methods (1LC and 2LC)* and machine learning (ML) method with all-cause mortality

MVPA						
daily]]	Dose (95% CI)			HR (95% CI)	
minutes		-	-		-	-
Methods	ML	1LC	2 LC	ML	1LC	2LC
ED100 (optimal duration)	32.0 (30.3, 33.9)	31.9 (30.0, 34.7)	9.3 (8.8, 10.4)	0.63 (0.53, 0.75)	0.60 (0.53, 0.69)	0.66 (0.58, 0.75)
ED75	19.5 (19.1, 20.1)	16.1(15.7, 16.7)	4.3 (4.1, 4.5)	0.72 (0.65, 0.81)	0.70 (0.64, 0.77);	0.74 (0.68, 0.81)
ED50 (minimum duration)	14.9 (14.6, 15.2)	11.1 (10.8, 11.4)	2.8 (2.6, 2.8)	0.82 (0.76, 0.87)	0.80 (0.76, 0.85)	0.83 (0.78, 0.88)
ED25	11.1 (11.0, 11.3)	7.2 (7.1, 7.4)	1.5 (1.5, 1.6)	0.91 (0.88, 0.94)	0.90 (0.88, 0.93)	0.92 (0.89, 0.94)
Median	32.2 (32.1, 32.3)	27.0 (26.9, 27.1)	7.2 (7.1, 7.3)	0.63 (0.53, 0.75)	0.65 (0.60, 0.75)	0.67 (0.59, 0.76)
MPA daily minutes						
Methods	ML	1LC	2 LC	ML	1LC	2LC
ED100						
(optimal duration)	-	-	-	-	-	-
ED75	21.0 (17.6, 29.9)	12.4 (11.9, 14.1)	3.7 (3.2, 5.8)	0.67 (0.58, 0.75)	0.73 (0.67, 0.80)	0.73 (0.66, 0.81)
ED50	14.9 (14.6,	8.6 (8.3,	2.3 (2.1,	0.77	0.82 (0.77,	0.82 (0.77,

Г

(minimum duration)	15	.2)	9.3	3)	2.	.8)	(0.70, 0.83)	0.87)	0.88)
ED25	10.1 11	(9.5, .1)	5.6 (5.9	5.5, 9)	1.3 1	(1.2, .5)	0.89 (0.86, 0.92)	0.91 (0.89, 0.94)	0.91 (0.88, 0.94)
Median	32.2 (32.1, 32.3)		19.9 (19.9, 20.0)		5.3 (5.3, 5.4)		0.60 (0.51, 0.70)	0.65 (0.58, 0.73)	0.68 (0.60, 0.77)
VPA daily									
Methods	ML		11	.C	2 LC		ML	1LC	2LC
ED100									
(optimal	-		-		-		-	-	-
duration)									
ED75	2.3 3,	(1.9, 3)	6.6 10.0)	(4.4,	1.8 5.0)	(1.2,	0.60 (0.52, 0.71)	0.69 (0.61, 0.78)	0.7 (0.62, 0.80)
ED50 (minimum duration)	1.4 1.7)	(1.3,	3.5 4.6)	(2.8,	0.8 1.2)	(0.7,	0.76 (0.69, 0.82)	0.79 (0.73, 0.86)	0.81 (0.75, 0.88)
ED25	0.9 1.0)	(0.8,	1.9 2.3)	(1.6,	0.4 0.5)	(0.3,	0.85 (0.81, 0.90)	0.90 (0.87, 0.93)	0.90 (0.86, 0.93)
Median	3.2 3.2)	(3.2,	6.9 7.0)	(6.9,	2.0 2.0)	(2.0,	0.53 (0.44, 0.64)	0.68 (0.60, 0.77)	0.69 (0.61, 0.79)

Note: If there was a nadir point in the dose-response curve, the optimal duration and the corresponding HRs would be presented; otherwise, a "-" would be presented, indicating no upper limit for the optimal dose.

Supplementary Table 3 The duration associated with the ED25, ED50, ED75, ED100 and the median of the intensities duration derived from cadence-based methods (1LC and 2LC)* and machine learning (ML) method with CVD mortality

MVPA							
daily]	Dose (95% CI))	HR (95% CI)			
minutes							
Methods	ML	1LC	2 LC	ML	1LC	2 LC	
ED100		22.0 (20.0	100 (102		0 (1 (0 47		
(optimal	-	32.0 (30.0,	18.0 (10.2,	-	0.61 (0.47,	0.58 (0.48,	
duration)		34.7) 19.9)			0.78)	0.76j	
	20.0 (19.0,	15.9 (15.1,	$F \in (4, 1, 0, 0)$	0.60 (0.50,	0.71 (0.59,	0.69 (0.58,	
ED12	23.5)	18.7)	5.0 (4.1,9.9)	0.71)	0.84)	0.83)	
ED50	150 (145	107 (103	30 (25	0.75 (0.68	0.81 (0.72	076 (066	
(minimum	15.0 (14.3, 16.6)	12.0	3.0 (2.3, 2.3)	0.73 (0.00,	0.01 (0.72,	0.70 (0.00,	
duration)	16.6)	12.0)	3.9]	0.823	0.90)	0.875	
	11.1 (10.8,	7.0 (6.7,	1.6 (1.4,	0.86 (0.82,	0.90 (0.86,	0.89 (0.84,	
EDZO	11.8)	7.5)	1.9)	0.91)	0.95)	0.94)	

Median	32.2 (32.1, 32.3)	27.0 (26.9, 27.1)	7.2 (7.1, 7.3)	0.49 (0.40, 0.61)	0.61 (0.48, 0.79)	0.59 (0.46, 0.77)
		,		,		
MPA daily minutes						
Methods	ML	1LC	2 LC	ML	1LC	2 LC
ED100 (optimal duration)	-	-	6.4 (5.4, 8.2)	-	-	0.64 (0.47, 0.87)
ED75	17.4 (16.8, 22.3)	13.6 (11.4, 19.9)	3.0 (2.8, 3.4)	0.65 (0.55, 0.77)	0.69 (0.56, 0.84)	0.73 (0.60, 0.88)
ED50 (minimum duration)	12.9 (12.5, 14.9)	9.1 (8.0, 12.6)	1.9 (1.8, 2.1)	0.77 (0.69, 0.85)	0.79 (0.70, 0.90)	0.82 (0.73, 0.92)
ED25	9.4 (9.2, 10.2)	5.5 (5.3, 7.0)	1.1(1.1, 1.2)	0.88 (0.84, 0.93)	0.90 (0.84, 0.95)	0.91 (0.87, 0.96)
Median	27.2 (27.1, 27.3)	19.9 (19.9, 20.0)	5.3 (5.3, 5.4)	0.54 (0.43, 0.68)	0.59 (0.43, 0.81)	0.64 (0.48, 0.86)
VPA daily						
minutes						
Methods	ML	1LC	2 LC	ML	1LC	2 LC
ED100 (optimal duration)	-	8.2 (7.1, 9.5)	-	-	0.61 (0.44, 0.85)	-
ED75	13.1 (4.1, 13.4)	3.9 (3.7, 4.2)	1.2 (0.4, 2.1)	0.55 (0.44, 0.69)	0.71 (0.58, 0.86)	0.60 (0.49, 0.75)
ED50 (minimum duration)	9.0 (7.4, 9.3)	2.5 (2.4, 2.7)	0.6 (0.4,0.9)	0.70 (0.60, 0.83)	0.81 (0.72, 0.91)	0.75 (0.67, 0.85)
ED25	5.3 (3.8, 5.7)	1.5 (1.4, 1.6)	0.3 (0.1, 0.4)	0.86 (0.80, 0.92)	0.90 (0.85, 0.96)	0.86 (0.81, 0.92)
Median	3.2 (3.2, 3.2)	6.9(6.9, 7.0)	2 (1.9, 2.0)	0.59 (0.47, 0.75)	0.62 (0.45, 0.83)	0.52 (0.40, 0.69)

Note: If there was a nadir point in the dose-response curve, the optimal duration and the corresponding HRs would be presented; otherwise, a "-" would be presented, indicating no upper limit for the optimal dose.

Supplementary table 4 The standardized duration associated with ED25, ED50, ED75, ED100 and the median of the intensities duration derived from cadence-based methods (1LC and 2LC)* and machine learning (ML) method with all-cause mortality

MVPA daily minutes	Stan	dardized min	utes	HR (95% CI)			
Methods	ML	1LC	2LC	ML	1LC	2LC	
ED2E	0.77	0.66	0.60	0.72	0.70 (0.64,	0.75 (0.68,	
ED25	-0.77	-0.00	-0.60	(0.65,	0.77)	0.82)	

				0.81)		
ED50				0.82	0.00 (0.75	0.02 (0.70
(minimum	-0.98	-0.82	-0.74	(0.76,	0.80 (0.75,	0.83 (0.78,
duration)				0.88)	0.85)	0.88)
				0.91		
ED75	-1.15	-0.95	-0.85	(0.88,	0.90 (0.88,	0.92 (0.89,
				0.94)	0.93)	0.94)
ED100				0.63		
(ontimal	-0.20	-0.14	-0.16	(0.53	0.60 (0.53,	0.66 (0.58,
duration)	0.20		0120	0.75)	0.69)	0.75)
uurutionj				0.63		
Median	-0.19	-0.30	-0.36	(0.53	0.61 (0.53,	0.67 (0.60,
Median	0.19	0.50	0.50	0.75)	0.70)	0.76)
				0.755		
MPA daily						
minutes						
Mothodo	MI	11.0	21.0	MI	110	21.0
Methous	ML	ILC	210		ILC	210
	0 5 4	0.00	0.50		0.73 (0.67,	0.75 (0.68,
EDZ 5	-0.54	-0.66	-0.59	(0.56,	0.80)	0.82)
				0.76		
ED50	0.07	0.0 F	0 7	0.78	0.82 (0.78,	0.83 (0.78,
(minimum	-0.86	-0.85	-0.75	(0.71,	0.87)	0.88)
duration)				0.84)		-
				0.89	0.91 (0.89,	0.92 (0.89,
ED75	-1.08	-0.99	-0.87	(0.85,	0.94)	0.94)
				0.92)	,	,
ED100	-	-0.04	0.06	-	0.64 (0.57,	0.66 (0.58,
(optimal)					0.73)	0.75)
				0.61	0.65	0.68(0.60
Median	-0.20	-0.27	-0.35	(0.52,	(0.58, 0.74)	0.77)
				0.71)	(0.00,0.7.7)	
VPA daily						
minutes						
Methods	ML	1LC	2LC	ML	1 LC	2LC
				0.61	0.69 (0.61	073(065
ED25	-0.57	-0.40	-0.44	(0.52,	0.09 (0.01,	0.82)
				0.71)	0.705	0.02)
ED50				0.73	0.80 (0.74	0.82 (0.76
(minimum	-0.77	-0.67	-0.62	(0.67,	0.00 (0.74,	0.02 (0.70,
duration)				0.81)	0.003	0.00J
ED75	-0.91	-0.81	-0.74	0.86	0.89 (0.86,	0.91 (0.88,

				(0.82,	0.93)	0.94)
				0.90)		
ED100						
(optimal	-	-	-	-	-	-
duration)						
				0.53	0 6 9 (0 6 0	071(062
Median	-0.31	-0.35	-0.39	(0.44,	0.88 (0.80,	0.71 (0.63,
				0.64)		0.01)

Note: If there was a nadir point in the dose-response curve, the optimal duration and the corresponding HRs would be presented; otherwise, a "-" would be presented, indicating no upper limit for the optimal dose.

Supplementary table 5 The standardized duration associated with the ED25, ED50, ED75, ED100 and the median of the intensities duration derived from cadence-based methods (1LC and 2LC)* and machine learning (ML) method with CVD mortality

MVPA						
daily	Star	idardized min	utes		HR (95% CI)	
minutes						
Methods	ML	1LC	2LC	ML	1LC	2 LC
	0.69	0.67	0 52	0.60 (0.51,	0.57 (0.48,	0.55 (0.45,
EDZO	-0.00	-0.67	-0.55	0.71)	0.67)	0.68)
ED50				072 (0 ()	0.71 (0.64	070 (0 (2
(minimum	-0.94	-0.84	-0.72	0.73 (0.00,	0.71 (0.64, 0.70)	0.70 (0.62,
duration)				-0.81)	0.795	0.79j
ED75	1 1 4	0.06	0.02	0.87 (0.83,	0.85 (0.82,	0.85 (0.80,
	-1.14	-0.96	-0.83	0.91)	0.90)	0.90)
ED100					0.40 (0.00	
(optimal	-	-0.06	-	-	0.42 (0.32,	_
duration)					0.55)	
Modian	0.10	0.20	0.26	0.49 (0.40,	0.44 (0.34,	0.49 (0.39,
median	-0.19	-0.30	-0.36	0.61)	0.56)	0.62)
MPA daily						
minutes						
Methods	ML	1LC	2LC	ML	1LC	2 LC
ED25	-0.70	-0.66	-0.64	0.65 (0.55,	0.68 (0.56,	0.73 (0.60,

				0.77)	0.84)	0.88)
ED50 (minimum duration)	-0.94	-0.85	-0.77	0.77 (0.69, 0.85)	0.79 (0.69, 0.90)	0.82 (0.72, 0.92)
ED75	-1.12	-1.0	-0.88	0.88 (0.84, 0.93)	0.90 (0.85, 0.95)	0.91 (0.86, 0.96)
ED100 (maximum duration)	0.09	0.002	-0.21	0.53 (0.42, -0.67)	0.58 (0.40, 0.83)	0.64 (0.47, 0.87)
Median	-0.20	-0.27	-0.35	0.54 (0.43, 0.68)	0.59 (0.43, 0.81)	0.64 (0.48, 0.86)
VPA daily						
-						
minutes						
minutes Methods	ML	1LC	2LC	ML	1LC	2 LC
minutesMethodsED25	ML 0.17	1LC -0.63	2LC -0.52	ML 0.55 (0.44, 0.69)	1LC 0.71 (0.58, 0.86)	2LC 0.61 (0.50, 0.76)
minutes Methods ED25 ED50 (minimum duration)	ML 0.17 -0.63	1LC -0.63 -0.75	2LC -0.52 -0.66	ML 0.55 (0.44, 0.69) 0.70 (0.59, 0.83)	1LC 0.71 (0.58, 0.86) 0.80 (0.71, 0.91)	2LC 0.61 (0.50, 0.76) 0.74 (0.65, 0.84)
minutes Methods ED25 ED50 (minimum duration) ED75	ML 0.17 -0.63 -0.83	1LC -0.63 -0.75 -0.85	2LC -0.52 -0.66 -0.76	ML 0.55 (0.44, 0.69) 0.70 (0.59, 0.83) 0.82 (0.75, 0.90)	1LC 0.71 (0.58, 0.86) 0.80 (0.71, 0.91) 0.90 (0.85, 0.96)	2LC 0.61 (0.50, 0.76) 0.74 (0.65, 0.84) 0.87 (0.82, 0.93)
minutes Methods ED25 ED50 (minimum duration) ED75 ED100 (optimal duration)	ML 0.17 -0.63 -0.83 -	1LC -0.63 -0.75 -0.85 -0.23	2LC -0.52 -0.66 -0.76 -	ML 0.55 (0.44, 0.69) 0.70 (0.59, 0.83) 0.82 (0.75, 0.90) -	1LC 0.71 (0.58, 0.86) 0.80 (0.71, 0.91) 0.90 (0.85, 0.96) 0.61 (0.44, 0.85)	2LC 0.61 (0.50, 0.76) 0.74 (0.65, 0.84) 0.87 (0.82, 0.93) -

Note: If there was a nadir point in the dose-response curve, the optimal duration and the corresponding HRs would be presented; otherwise, a "-" would be presented, indicating no upper limit for the optimal dose.